Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET
Company Participants
Andrea Flynn - VP and Head, IR
Bruce Cozadd - Chairman and CEO
Dan Swisher - President
Rob Iannone - EVP, Global Head of R&D
Renée Galá - EVP and CFO
Kim Sablich - EVP and General Manager, North America
Conference Call Participants
Ken Cacciatore - Cowen
Jessica Fye - JPMorgan
Jason Gerberry - Bank of America
David Amsellem - Piper Sandler
Marc Goodman - SVB
Ami Fadia - Needham
Ash Verma - UBS
Madhu Kumar - Goldman Sachs
Gary Nachman - BMO Capital Markets
Annabel Samimy - Stifel
Gregory Renza - RBC Capital
Operator
Good day, and thank you for standing by. Welcome to the Q3 2022 Jazz Pharmaceuticals Earnings Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions]
I would now like to hand the conference over to your speaker today, Andrea Flynn, Vice President, Vice President of Investor Relations. Please go ahead.
Andrea Flynn
Thank you, operator and good afternoon, everyone. Today, Jazz Pharmaceuticals reported its third quarter 2022 financial results. The slide presentation accompanying this webcast is available on the Investors section of our website. Investors may also refer to the press release we issued earlier today, which is also posted to our website.
On the call today are Bruce Cozadd, Chairman, and Chief Executive Officer; Renée Galá, Executive Vice President and Chief Financial Officer; Dan Swisher, President and Chief Operating Officer; and Rob Iannone, Executive Vice President, Global Head of R&D. Kim Sablich, Executive Vice President and General Manager, US, will join the team for Q&A.
On slide two, I’ll remind you that today’s webcast includes forward-looking statements such as those related to our future financial and operating results, including expectations related to Vision 2025 and our guidance for 2022, growth potential and anticipated development programs and pipeline, regulatory activities and commercialization milestones, goals and expected timing, and statements with respect to our licensing agreement for Zanidatamab that is subject to closing condition, which involve risks and uncertainties that could cause actual events, performance, and results to differ materially from those contained in these forward-looking statements.
We encourage you to review the statements contained in today’s press release, in our slide deck, and in our latest SEC disclosure document, which identify certain factors that may cause the company’s actual events, performance, and results to differ materially from those contained in the forward-looking statements made on today’s webcast. We undertake no duty or obligation to update our forward-looking statements.